Search

Saul Jaime-Figueroa

from Morris Plains, NJ

Get Report
Related to:
Connected to:

Saul Jaime-Figueroa Phones & Addresses

  • Morris Plains, NJ

Us Patents

  • Inhibitors Of Bruton's Tyrosine Kinase

    view source
  • US Patent:
    8481540, Jul 9, 2013
  • Filed:
    Aug 11, 2011
  • Appl. No.:
    13/207481
  • Inventors:
    Steven Joseph Berthel - Mendham Township NJ, US
    Roland Joseph Billedeau - Clifton NJ, US
    Christine E. Brotherton-Pleiss - Sunnyvale CA, US
    Fariborz Firooznia - Florham Park NJ, US
    Stephen Deems Gabriel - Morristown NJ, US
    Xiaochun Han - Cedar Grove NJ, US
    Ramona Hilgenkamp - Montclair NJ, US
    Saul Jaime-Figueroa - Morris Plains NJ, US
    Buelent Kocer - Hoboken NJ, US
    Francisco Javier Lopez-Tapia - Mahwah NJ, US
    Yan Lou - Clifton NJ, US
    Lucja Orzechowski - Kinnelon NJ, US
    Timothy D. Owens - Jersey City NJ, US
    Jenny Tan - New Providence NJ, US
    Peter Michael Wovkulich - Nutley NJ, US
  • Assignee:
    Hoffmann-La Roche Inc. - Nutley NJ
  • International Classification:
    A01N 43/58
    A61K 31/50
    C07D 237/00
  • US Classification:
    514248, 544237
  • Abstract:
    This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I:.

  • Deprotection Of Boc-Protected Compounds

    view source
  • US Patent:
    20100311968, Dec 9, 2010
  • Filed:
    Jun 9, 2010
  • Appl. No.:
    12/797343
  • Inventors:
    Jason Chi-Chung Choy - Alameda CA, US
    Saul Jaime-Figueroa - Morris Plains NJ, US
  • International Classification:
    C07F 7/18
    C07C 45/65
    C07C 37/055
    C07F 5/02
    C07C 27/00
    C07C 51/09
    C07D 213/55
    C07D 235/26
  • US Classification:
    544229, 568433, 568716, 568 6, 568812, 562493, 546327, 5483064
  • Abstract:
    Organic compounds having t-butyl ester or BOC carbonate protecting groups are effectively deprotected by heating in a fluorinated alcohol solution.

  • Pyrrolopyrazine Kinase Inhibitors

    view source
  • US Patent:
    20110288067, Nov 24, 2011
  • Filed:
    May 18, 2011
  • Appl. No.:
    13/110062
  • Inventors:
    Robert Than Hendricks - San Carlos CA, US
    Johannes Hermann - Morris Plains NJ, US
    Saul Jaime-Figueroa - Morris Plains NJ, US
    Rama Kondru - Morris Plains NJ, US
    Yan Lou - Clifton NJ, US
    Stephen Lynch - Westfield NJ, US
    Timothy D. Owens - Jersey City NJ, US
    Michael Soth - Glen Rock NJ, US
    Calvin Yee - Nutley NJ, US
  • International Classification:
    A61K 31/4985
    C07D 295/155
    C07D 491/107
    A61K 31/541
    A61P 29/00
    A61P 37/00
    A61P 35/00
    A61P 25/00
    A61P 9/00
    A61P 3/10
    A61P 37/04
    A61P 11/06
    A61P 19/04
    A61P 17/06
    A61P 37/06
    A61P 17/00
    A61P 5/14
    A61P 1/04
    A61P 1/00
    A61P 25/28
    A61P 35/02
    C07D 487/04
  • US Classification:
    51421016, 544350, 544 582, 544230, 514249, 51421018, 5142285
  • Abstract:
    The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I,wherein the variables Q and R, R, and Rare defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  • Inhibitors Of Bruton's Tyrosine Kinase

    view source
  • US Patent:
    20130045965, Feb 21, 2013
  • Filed:
    Aug 16, 2012
  • Appl. No.:
    13/586958
  • Inventors:
    Christine E. Brotherton-Pleiss - Sunnyvale CA, US
    Saul Jaime-Figueroa - Morris Plains NJ, US
    Francisco Javier Lopez-Tapia - Mahwah NJ, US
    Yan Lou - Glen Ridge NJ, US
    Timothy D. Owens - San Carlos CA, US
  • International Classification:
    A61K 31/501
    A61K 31/502
    C07D 413/14
    A61P 11/06
    C07D 401/14
    C07D 405/14
    A61P 29/00
    A61P 19/02
    A61K 31/5377
    C07D 487/04
  • US Classification:
    51421021, 5142345, 514248, 51425202, 544119, 544237, 544238
  • Abstract:
    This application discloses compounds according to generic Formula I:wherein the variables are defined as described herein, and which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

  • Inhibitors Of Bruton's Tyrosine Kinase

    view source
  • US Patent:
    20130178461, Jul 11, 2013
  • Filed:
    Mar 1, 2013
  • Appl. No.:
    13/781815
  • Inventors:
    Roland Joseph Billedeau - Santa Clara CA, US
    Christine E. Brotherton-Pleiss - Sunnyvale CA, US
    Fariborz Firooznia - Florham Park NJ, US
    Stephen Deems Gabriel - Morristown NJ, US
    Xiaochun Han - Cedar Grove NJ, US
    Ramona Hilgenkamp - Montclair NJ, US
    Saul Jaime-Figueroa - Morris Plains NJ, US
    Buelent Kocer - Shanghai, CN
    Francisco Javier Lopez-Tapia - Mahwah NJ, US
    Yan Lou - Pleasanton CA, US
    Lucja Orzechowski - Kinnelon NJ, US
    Timothy D. Owens - San Carlos CA, US
    Jenny Tan - New Providence NJ, US
    Peter Michael Wovkulich - Nutley NJ, US
  • Assignee:
    Hoffmann-La Roche Inc. - Nutley NJ
  • International Classification:
    C07D 401/14
    C07D 405/14
    C07D 487/04
  • US Classification:
    51421021, 544114, 5142352, 544238, 51425204, 514249
  • Abstract:
    This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I:wherein, variables X, R, and Y, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

  • Compounds And Methods For The Targeted Degradation Of Rapidly Accelerated Fibrosarcoma Polypeptides

    view source
  • US Patent:
    20230000994, Jan 5, 2023
  • Filed:
    Jul 28, 2021
  • Appl. No.:
    17/387621
  • Inventors:
    - New Haven CT, US
    Jing Wang - Milford CT, US
    Saul Jaime-Figueroa - Morris Plains NJ, US
    Hanqing Dong - Madison CT, US
    Lawrence B. Snyder - Killingworth CT, US
  • International Classification:
    A61K 47/55
    C07D 471/04
    C07D 519/00
    C07D 417/14
    C07D 413/14
  • Abstract:
    The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  • Egfr Proteolysis Targeting Chimeric Molecules And Associated Methods Of Use

    view source
  • US Patent:
    20210220475, Jul 22, 2021
  • Filed:
    Mar 4, 2021
  • Appl. No.:
    17/192083
  • Inventors:
    - New Haven CT, US
    Jing Wang - Milford CT, US
    Craig M. Crews - New Haven CT, US
    Saul Jaime-Figueroa - Morris Plains NJ, US
    George Burslem - Sandwich, GB
  • International Classification:
    A61K 47/54
    A61K 47/55
    A61K 31/519
    A61K 31/427
    A61K 31/454
    A61K 31/517
    A61K 31/55
    A61K 31/496
    A61K 31/551
    A61K 45/06
    A61K 38/07
    A61K 31/52
    A61K 31/506
    C07D 471/04
  • Abstract:
    The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) TBK1. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds TBK1 such that TBK1 is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of TBK1. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of TBK1.

  • Proteolysis Targeting Chimera Compounds And Methods Of Preparing And Using Same

    view source
  • US Patent:
    20200325130, Oct 15, 2020
  • Filed:
    Apr 14, 2020
  • Appl. No.:
    16/848290
  • Inventors:
    - New Haven CT, US
    Momar TOURE - New Haven CT, US
    Eunhwa KO - Dong-gu, KR
    Saul JAIME-FIGUEROA - Morris Plains NJ, US
  • International Classification:
    C07D 417/14
    C07K 5/06
    C07K 5/062
    A61K 47/55
    A61K 47/54
  • Abstract:
    The present invention includes novel compounds and methods for preventing or treating diseases associated with and/or caused by overexpression and/or uncontrolled activation of a tyrosine kinase in a subject in need thereof. In certain embodiments, the compounds of the present invention comprise a tyrosine kinase inhibitor, a linker and a ubiquitin ligase binder. The methods of the present invention comprise administering to the subject an pharmaceutically effective amount of at least one compound of the invention.
Get Report for Saul Jaime-Figueroa from Morris Plains, NJ
Control profile